Figure 2. Accelerated Approval Drugs With the Highest Medicare Spending, 2015-2019.

Estimated spending for the top 10 Medicare Part B drugs (A) and Part D drugs (B) during the time from 2015 through 2019 that a drug had an accelerated approval indication on the label, including time when the drug was marketed exclusively via accelerated approval (blue) or time when the drug had other labeled indications via traditional US Food and Drug Administration approval pathways (orange).